Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217587 · ClinicalTrials.gov registry record · Phase 3
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
A Phase 3 study of Myasthenia Gravis, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
- 7
- Study locations
NCT07217587 is a Phase 3 study of Myasthenia Gravis that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 115 participants, below the 188-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (39% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT07217587, a Phase 3 study of Myasthenia Gravis, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
Conditions Studied
Interventions
- DRUG Nipocalimab
- DRUG Efgartigimod
Study Locations (7)
Other
- Rambam Medical Center - Haifa
- Sourasky Medical Center - Tel Aviv
Connecticut
- University of Connecticut - Farmington
Florida
- SFM Clinical Research LLC - Boca Raton
Illinois
- HSHS St. Elizabeth's Hospital - O'Fallon
Michigan
- Henry Ford Hospital - Detroit
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2028-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217587
The ClinicalTrials.gov registry entry for NCT07217587 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (39% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Nipocalimab is the first listed.
NCT07217587 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT07217587 about?
NCT07217587 is a clinical study titled "Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis". The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
What is the current status of trial NCT07217587?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2026-01-05. Estimated completion is 2028-12-11.
What conditions does trial NCT07217587 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT07217587?
The interventions under investigation include: Nipocalimab (DRUG), Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT07217587?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217587 being conducted?
This trial has 7 study locations across Connecticut, Florida, Illinois, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Myasthenia Gravis Inebilizumab Trial
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
-
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
COMPLETED · Phase 3
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.